Clinical Research Directory
Browse clinical research sites, groups, and studies.
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Sponsor: Hospital Israelita Albert Einstein
Summary
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Official title: Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial
Key Details
Gender
All
Age Range
1 Year - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2018-11-06
Completion Date
2026-11-01
Last Updated
2019-02-01
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide
Cyclophosphamide 1000 mg/flask
ATG
Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
Locations (1)
Hospita Israelita Albert Eintein
São Paulo, São Paulo, Brazil